세계 기능적 서비스 프로바이더(FSP) 시장 예측(-2027년)

Market Overview

The Functional Service Providers (FSP) is anticipated to register a healthy CAGR of 7.49% during the review period.

This market is being driven by various elements, including expanding Research and development ventures, the rising number of clinical preliminaries, and the ascent of FSP outsourcing in drug improvement.

Rising Research and development speculations, particularly in the biopharmaceutical and biotechnology businesses, have made a requirement for functional service providers (FSPs) in the worldwide market. Research showed that the utilization of FSPs by enormous biopharmaceutical organizations is developing at a pace of over 13% yearly. These service providers offer staff to biopharmaceutical and biotechnology organizations for their exploration and advancement projects. They give profoundly qualified research partners, information supervisors, concentrate on organizers, clinical screens, and other related staff backing to these organizations.

Moreover, FSPs offer arrangements like preliminary administration, clinical checking, information the executives, factual programming, biostatistics, clinical composition, lifecycle security, and administrative undertakings. The tedious and costly nature of clinical preliminaries and the issues brought about by the high responsibility bring about the rising notoriety of FSPs. These providers save the organization time and lessen functional expenses.

Segment Insights

Segmentation of the global functional service provider market by type includes clinical monitoring, medical publishing, data management, pharmacovigilance, biostatistics/programming, regulatory, and others.

Based on phase, the global functional service provider market has been segmented into clinical trial phase and post-approval phase. Based on applications, the global functional service providers industry has been segmented into biopharmaceutical companies, biotechnology companies, medical device companies, and research centers and hubs. University institutes.

Regional Insights

The North America functional service providers market represented the biggest market with a portion of roughly 41% in 2022, because of the created medical care foundation, countless clinical preliminaries, and the presence of significant central participants in the region like IQVIA (US), Parexel (US), and Labcorp Medication Improvement (US).

Europe functional service supplier market represented the second-biggest market share because of innovation headways, expanding medical care consumption, and expanding predominance of ongoing sicknesses. As per the EMA, around 4,000 clinical preliminaries happen consistently across the European Association (EU) nations. Moreover, the Germany functional service supplier held the biggest market share in 2022, and the France functional service providers is extended be the quickest developing market in the Europe region.

The Asia-Pacific functional service providers market is supposed to be the quickest developing from 2023 to 2027 attributable to high understanding populace, decreased expenses of leading preliminaries, and great administrative arrangements. Also, central members working in the Functional Service Providers (FSP) Market are effectively venturing into Asia-Pacific region. For example, in July 2018, Parexel (US) laid out another auxiliary called Wellbeing Advances in Hong Kong to grow its capacities in the APAC region.

Major Players

Key Companies in the Functional Service Providers Market are Quanticate International Limited (UK), IQVIA, Inc. (US), BioPoint Inc. (US), Rho, Inc. (US), KPS Life, LLC (US), Parexel International Corporation (US), Laboratory Corporation of America Holdings (US), Wuxi Apptec co., Ltd. (China), Icon Plc (Ireland), and PPD Inc. (US).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING R&D INVESTMENTS
  • 4.2.2 RISING NUMBER OF CLINICAL TRIALS
  • 4.2.3 LOWERED OPERATIONAL COSTS AND IMPROVED SERVICE QUALITY
  • 4.2.4 RISE IN FSP OUTSOURCING IN DRUG DEVELOPMENT
• 4.3 RESTRAINTS
  • 4.3.1 DEARTH OF SKILLED LABOR
• 4.4 OPPORTUNITIES
  • 4.4.1 BIOPHARMA AND BIOTECH'S DIGITAL TRANSFORMATION

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 CUSTOMER ACQUISITION (PREPURCHASE QUERY)
  • 5.1.2 SERVICE CUSTOMIZATION
  • 5.1.3 CUSTOMER PURCHASE SUPPORT
  • 5.1.4 CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON FUNCTIONAL SERVICE PROVIDERS MARKET
  • 5.3.1 OVERVIEW
  • 5.3.2 IMPACT ON DEMAND FOR FUNCTIONAL SERVICE PROVIDERS (FSP)

6 GLOBAL FUNCTIONAL SERVICE PROVIDERS MARKET BY TYPE

• 6.1 OVERVIEW
• 6.2 CLINICAL MONITORING
• 6.3 MEDICAL WRITING
• 6.4 DATA MANAGEMENT
• 6.5 PHARMACOVIGILANCE
• 6.6 BIOSTATISTICS/PROGRAMMING
• 6.7 REGULATORY AFFAIRS
• 6.8 OTHERS

7 GLOBAL FUNCTIONAL SERVICE PROVIDERS MARKET BY STAGE

• 7.1 OVERVIEW
• 7.2 CLINICAL DEVELOPMENT
• 7.3 POST APPROVAL

8 GLOBAL FUNCTIONAL SERVICE PROVIDERS MARKET BY APPLICATION

• 8.1 OVERVIEW
• 8.2 BIOPHARMA COMPANIES
• 8.3 BIOTECH COMPANIES
• 8.4 MEDICAL DEVICES COMPANIES
• 8.5 RESEARCH CENTER AND ACADEMIC INSTITUTES

9 GLOBAL FUNCTIONAL SERVICE PROVIDERS MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 UK
  • 9.3.3 FRANCE
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 JAPAN
  • 9.4.3 INDIA
  • 9.4.4 AUSTRALIA
  • 9.4.5 SOUTH KOREA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 LATIN AMERICA
  • 9.5.2 MIDDLE EAST
  • 9.5.3 AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 COMPETITIVE BENCHMARKING
• 10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL FUNCTIONAL SERVICE PROVIDERS MARKET
• 10.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL FUNCTIONAL SERVICE PROVIDERS MARKET
• 10.5 KEY DEVELOPMENT ANALYSIS
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 PRODUCT LAUNCHES
  • 10.6.2 PARTNERSHIPS
  • 10.6.3 ACQUISITIONS
• 10.7 MAJOR PLAYERS FINANCIAL MATRIX
  • 10.7.1 SALES (USD MILLION), 2022
  • 10.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2022

11 COMPANY PROFILES

• 11.1 IQVIA INC.
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 SOLUTIONS/SERVICES OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 LABORATORY CORPORATION OF AMERICA HOLDINGS
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS/SERVICES OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 ICON PLC
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS/SERVICES OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGIES
• 11.4 KPS LIFE, LLC
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS/SERVICES OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 KEY STRATEGIES
• 11.5 WUXI APPTEC CO., LTD.
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 SOLUTIONS/SERVICES OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 SWOT ANALYSIS
  • 11.5.6 KEY STRATEGIES
• 11.6 PPD INC.
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 SOLUTIONS/SERVICES OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 KEY STRATEGIES
• 11.7 PAREXEL INTERNATIONAL CORPORATION
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS/SERVICES OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 KEY STRATEGIES
• 11.8 QUANTICATE INTERNATIONAL LIMITED
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS/SERVICES OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 KEY STRATEGIES
• 11.9 BIOPOINT INC.
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS/SERVICES OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 RHO, INC.
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS/SERVICES OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 KEY STRATEGIES

12 APPENDIX

• 12.1 REFERENCES
• 12.2 RELATED REPORTS